Paper Details

  1. Home
  2. Paper Details

Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.

Author: BrownPaul D, CerhanJane L, JaeckleKurt A, KizilbashSani H, KohliSadhna, Le-RademacherJennifer, LiuHeshan, LoprinziCharles L, McMurrayRyan P, MehtaMinesh P, PorterAlyx B, SloanJeff, VillanoJohn L

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A phase 3 clinical trial found no meaningful benefit of armodafinil in reducing cancer-related fatigue in patients with high-grade glioma (HGG). Armodafinil did not significantly improve fatigue scores compared to placebo. The study highlights the need for further research into effective treatments for fatigue in patients with HGG.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Nearly 96% of patients with high-grade glioma (HGG) report moderate-to-severe fatigue. Armodafinil is a psychostimulant that might help cancer-related fatigue in patients with HGG. OBJECTIVE: To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662535/

データ提供：米国国立医学図書館（NLM）

Armodafinil: A Potential Oasis in the Desert of Cancer-Related Fatigue?

This research delves into the challenging landscape of cancer-related fatigue, a common and debilitating side effect for many patients. The study examines the potential benefits of armodafinil, a psychostimulant, in alleviating fatigue in individuals with high-grade glioma (HGG). The researchers meticulously designed a randomized clinical trial to assess the efficacy of armodafinil in reducing fatigue. They carefully evaluated the results, hoping to find an oasis of relief in this challenging desert of cancer-related fatigue.

Searching for a Solution

Unfortunately, the results of this study showed no significant difference in fatigue reduction between patients receiving armodafinil and those receiving a placebo. The researchers carefully analyzed the data, hoping to find a glimmer of hope, but the results were inconclusive. It's like searching for water in a vast desert and finding only dry sand. The search for effective treatments for cancer-related fatigue continues.

A Continued Quest for Relief

This research emphasizes the need for ongoing research to find effective treatments for cancer-related fatigue. Imagine researchers diligently exploring the desert, searching for hidden oases of hope. This study serves as a reminder that the journey to combat cancer-related fatigue is long and complex, but the search for solutions continues.

Dr.Camel's Conclusion

While armodafinil did not prove to be a solution in this study, the search for effective treatments continues. The quest for relief from cancer-related fatigue is a challenging one, but researchers remain dedicated to finding solutions. Just as a traveler in the desert never stops searching for water, researchers are committed to finding ways to alleviate the burden of this debilitating side effect.

Date :
  1. Date Completed 2022-03-14
  2. Date Revised 2022-12-10
Further Info :

Pubmed ID

34882169

DOI: Digital Object Identifier

PMC8662535

Related Literature

Article Analysis
・Effects of armodafinil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.